A 68-year-old man from Delhi presents with progressive lower urinary tract symptoms (LUTS) for 8 months: nocturia (4 times/night), weak urinary stream, and post-void dribbling. Digital rectal examination reveals a smooth, firm, symmetrically enlarged prostate. Serum PSA is 2.8 ng/mL. Uroflowmetry shows peak flow of 8 mL/s (normal >15 mL/s). Post-void residual urine is 120 mL. He denies dysuria, hematuria, or acute retention. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has symptomatic benign prostatic hyperplasia (BPH) with objective evidence of obstruction (low peak flow, elevated post-void residual) but no acute retention or refractory symptoms. ## Management Algorithm for BPH ```mermaid flowchart TD A[Symptomatic BPH confirmed]:::outcome --> B{Acute retention or<br/>refractory symptoms?}:::decision B -->|Yes| C[Invasive therapy:<br/>TURP/laser/open]:::action B -->|No| D{Mild-moderate<br/>symptoms?}:::decision D -->|Yes| E[Alpha-blocker monotherapy<br/>4-6 week trial]:::action D -->|No| F[Combination therapy:<br/>Alpha-blocker + 5-ARI]:::action E --> G{Symptom response?}:::decision G -->|Good| H[Continue, monitor]:::outcome G -->|Poor| I[Add 5-ARI or switch<br/>to invasive therapy]:::action ``` ## Rationale for Alpha-Blocker First-Line **Key Point:** Alpha-blockers (tamsulosin, alfuzosin, doxazosin) are the **first-line pharmacological agent** for symptomatic BPH with moderate LUTS and no acute retention [cite:Harrison 21e Ch 297]. **High-Yield:** Alpha-blockers work by relaxing smooth muscle in the prostate and bladder neck, providing rapid symptom relief (onset 1–2 weeks). They do NOT reduce prostate size. **Clinical Pearl:** A 4–6 week trial is standard to assess response. If symptoms improve by ≥25% on IPSS score, continue; if inadequate, add a 5-alpha reductase inhibitor (finasteride/dutasteride) for combination therapy. ## Why This Patient Qualifies for Medical Management | Feature | Status | Implication | |---------|--------|-------------| | Acute retention | Absent | Not an emergency | | Refractory symptoms | No | Not yet failed medical therapy | | Peak flow | 8 mL/s (low) | Obstructive, but not absolute contraindication to medical trial | | Post-void residual | 120 mL | Elevated but <150 mL; acceptable for conservative start | | PSA | 2.8 ng/mL | No cancer concern | **Tip:** The presence of objective obstruction (low flow, elevated PVR) does NOT mandate immediate TURP in an asymptomatic or mildly symptomatic patient. Medical therapy should be attempted first unless the patient has acute retention, recurrent UTIs, or refractory symptoms despite optimal medical management. ## When to Escalate to Invasive Therapy - Acute urinary retention (spontaneous or catheter-dependent) - Recurrent UTIs attributable to residual urine - Recurrent gross hematuria from BPH - Bladder stones or upper urinary tract dilatation secondary to BPH - Failure or intolerance of medical therapy after ≥6 months ## 5-Alpha Reductase Inhibitors: Role **Key Point:** 5-ARIs (finasteride, dutasteride) reduce prostate volume by ~25% and are **reserved for**: - Large prostates (>40 g on imaging) - Combination therapy with alpha-blocker after inadequate monotherapy response - Prevention of BPH progression in high-risk men 5-ARIs have slower onset (3–6 months) and are NOT used as monotherapy for initial symptom relief.